Exploringlandscape cell receptors

Exploring the landscape of cell receptors

7:53 AM, 10th May 2016
Exploring the landscape of cell receptors
Professor Scott Prosser and post-doc Libin Ye, explained about the class of receptors responsible for regulating neuronal function.

TORONTO, US: Ever wonder how caffeine works so marvellously to give you that extra boost you need the night before your final exam?

The caffeine molecule—much loved by students the world over—binds to a receptor, preventing the action of the sleep-inducing molecule adenosine, giving you those extra few hours to prepare for your exam in the morning.

The class of receptors responsible for regulating neuronal function are part of the focus of a recent study by professor Scott Prosser in the Department of Chemical & Physical Sciences at University Of Toronto, Mississauga (UTM).

Their study is published in the journal Nature.

The research also involved UTM postdoctoral scientist, Libin Ye, and Oliver Ernst in the Department of Biochemistry.

There is a great deal of interest in understanding this class of cell signalling receptors called GPCRs (G-Protein-Coupled Receptors), which are responsible for basic processes such as vision, taste, smell, chemical signalling in the brain and immune defence. Roughly 30 to 40 percent of current drugs target these receptors, which essentially serve as gatekeepers for cell signalling.

“With our latest findings, we can begin to design the next generation of GPCR drugs,” said Prosser.

He explained that GPCRs are often likened as molecular switches, which are blocked or turned on or off by drugs. Since 2007, a technique called X-ray crystallography has revealed a wealth of high-resolution structures of these “switches.” Prosser's studies allow researchers to understand the molecular underpinnings of many pharmacological effects.

“This work delves further into the conformational landscape of these neuronal receptors, which are some of the most important drug targets in inflammation, cancer, sickle cell disease, diabetes, and brain disorders such as Parkinson’s disease,” said Prosser.

© University Of Toronto News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

PKN Orlen signs long-term supply contract with Saudi Aramco

PLOCK, POLAND: PKN Orlen SA has signed a contract with Saudi Aramco, for the supply of some 200,000 tonnes of crude oil monthly to its refineries, eff ...

Read more
Sinopec names senior VP Dai as new president, director

BEIJING, CHINA: Sinopec Group said that it has appointed Dai Houliang as the company’s new president, director and vice party chief, replacing W ...

Read more
DyStar to acquire Emerald's speciality chemical units

SINGAPORE: DyStar LP, a US subsidiary of DyStar Global Holdings Pte Ltd, said that it has entered into an agreement to acquire five speciality chemica ...

Read more
Total to acquire French battery maker Saft in €950 mn deal

PARIS, FRANCE: Total SA has signed an agreement to acquire all the outstanding shares of French battery maker, Saft Groupe SA in a deal valued at &eur ...

Read more
Ube, Mitsubishi Rayon, JSR to merge ABS subsidiaries

TOKYO, JAPAN: Ube Industries Ltd, Mitsubishi Rayon Co Ltd, and JSR Corporation have reached an agreement to merge their respective subsidiaries in the ...

Read more
Westlake awards scholarships to 50 college students of employees

HOUSTON, US: Westlake Chemical Corporation said that they recently notified 50 college-bound students of employees that they are recipients of a Westl ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X